AbiProt® scans the whole intact protein surface using molecular drones and identifies high value antibody binding sites.
Our patented biologics platform technology AbiProt® identifies new therapeutic antibodies that not only bind to a target protein with high specificity and affinity — in many cases they can also be programmed to have a particular pharmacological action. We believe the technology will enable the development of more effective medicines against target proteins that cannot be addressed with traditional antibody technology.
Our proprietary platform technology Abiprot® can identify high-affinity antibody binding sites in any given protein with single amino acid resolution. It is based on using a tailored molecular reporter system and proteomics. The platform yields detailed sequence and structure information for epitope identification and development.
Abiprot® works well with both soluble and membrane bound proteins, and, in some instances, we can also control the pharmacology of our antibodies by careful selection of epitopes to yield either antagonistic or agonistic antibodies.
Trkulja C.L. et al; Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular Probes. Science Advances 16 Apr 2021; Vol. 7, no. 16, eabe6397
Trkulja C.L. et al; Probing Structure and Function of Ion Channels Using Limited Proteolysis and Microfluidics. J. Am. Chem. Soc. 2014; 136, 42, 14875–14882